Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Archon Biosciences

Request full access

Creates computationally designed proteins to target and treat diseases that current methods cannot

Seattle, United StatesFounded 2023Biotech & Life Sciences

About Archon Biosciences

Archon Biosciences is a biotechnology firm that emerged from stealth in October 2024 with $20 million in seed financing to develop its proprietary Antibody Cages (AbCs). Founded in 2023, the company is a spinout from the University of Washington's Institute for Protein Design (IPD), leveraging technology developed in the lab of Nobel laureate Dr. David Baker, who is also a co-founder. The other co-founders are CEO James Lazarovits, CTO George Ueda, and Lance Stewart. Lazarovits holds a Ph.D. in nanotechnology engineering and was a research faculty member at the IPD, while Ueda spent over a decade at the IPD under Dr. Baker's mentorship. Their research, which formed the basis for Archon, was initially published in 2021 and received over $7 million in grant funding prior to the seed round.

The company's core focus is on a novel class of biologics called Antibody Cages, which are designed to overcome the limitations of traditional antibody therapeutics. Archon utilizes computational protein design and generative AI to create these AbCs, which are new protein structures that combine with existing antibodies. This approach allows for precise control over the geometric structure of the antibody, which in turn influences how it is distributed in the body and how it engages with cellular targets. The key innovation lies in modifying the antibody's structure without altering its amino acid sequence, viewing it as a "bolt-on solution" to enhance its properties. This method aims to create more effective and safer therapeutics by improving target engagement and minimizing off-target effects, potentially rescuing drugs that previously failed in clinical trials due to efficacy issues.

Archon's business model revolves around developing a proprietary platform that can rapidly design, manufacture, and test new AbC candidates for various diseases, with an initial focus on oncology. The technology is designed to be a modular platform, allowing for the efficient creation of different drugs for diverse applications. The company serves the biopharmaceutical market by aiming to develop its own pipeline of drug candidates while also being open to partnerships with larger pharmaceutical companies. By creating a platform that interfaces with the industry-standard antibody format, Archon seeks to establish a new gold standard in biologic drug development. The company has stated its first targets are conditions without currently approved antibody treatments and is pursuing acute, not chronic, therapies.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2023
Headquarters
Seattle, United States
Employees
26
Open positions
None listed
Dealroom signal
74.6/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotech & Life Sciences, Biotechnology, Antibodies, Spinout, Biotech and Pharma, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SEED✓Equity / VC Oct 2024 $20M $80M Alexandria Venture Investments · DUMAC · Cornucopian Capital · WRF Capital ↗
SPINOUT✓Other financing Jan 2023 $0 — University of Washington —
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Archon Biosciences website traffic

Latest recorded traffic for Archon Biosciences is 2.1K monthly website visits, down 34.4% over the last three months. Archon Biosciences's team declined 3.7% over the past year.

Latest monthly visits2.1K 3-month web change-34.4% 1-year team growth-3.7%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Archon Biosciences in the Seattle ecosystem

Live from Dealroom

The Archon Biosciences office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

8 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed7 investors entered at this stage

  • Madrona Venture Group
  • Alexandria Venture Investments
  • DUMAC
  • Cornucopian Capital
  • WRF Capital
  • Sahsen Ventures
  • Pack Ventures

Other known investors1 additional known investor

  • University of Washington
Team profiled 3 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
3 countries with
team presence
🇺🇸 United States78.3%
🇨🇦 Canada17.4%
🇧🇩 Bangladesh4.3%
3 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Archon Biosciences on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Archon Biosciences’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.